Results from a randomized controlled trial exhibited that subcutaneous administration of denosumab every 6 months significantly reduced clinical fracture rates and significantly delayed time to first fracture in postmenopausal patients with hormone receptor-positive early-stage breast cancer treated with adjuvant aromatase inhibitors (91). Here, CYP19A1 is linked to breast carcinoma.